Abstract: The invention relates generally to biotechnology and medicine and to sources and salts of autophagy inhibiting peptides useful as pharmaceutical compounds. In particular, the invention provides method for reducing formyl-peptide-receptor (FPR) mediated p38 MAPK kinase activity of cells comprising providing said cells with a source of amino acids said source comprising at least 50%, more preferably at least 75%, most preferably at 100% amino acids selected from the group of autophagy inhibiting amino acids alanine (in one letter code: A), glutamine (Q), glycine (G), valine (V), leucine (L), proline (P), and arginine (R).

Abstract: Provided is a method of treatment comprising administering an AQGV peptide, or a functional analogue thereof, to a human subject, the human subject suffering from an infection, particularly a respiratory infection, more specifically, a viral infection, more in particular, a Corona virus infection, wherein the treatment of administering an AQGV peptide comprises maintaining or improving hemodynamic stability in the human subject.

Abstract: A first aspect of the invention relates to a method for eradicating tumor cells expressing on their surface a MHC/peptide complex comprising a peptide derived from MAGE comprising contacting said cell with at least one immune effector cell through specific interaction of a specific binding molecule for said MHC/peptide complex. Described are bispecific immunoglobulins of which one arm specifically binds to a MHC/MAGE-derived peptide complex associated with aberrant cells, and the other arm specifically recognizes a target associated with immune effector cells. The present invention relates to a pharmaceutical composition comprising such bispecific antibody and suitable diluents and/or excipients.

Abstract: Described are proteinaceous molecules comprising at least two, preferably three to six, binding domains that bind specifically to at least two different binding sites on aberrant cells. These multi-domain and multi-specific binding molecules are preferably used in selectively modulating biological processes. The provided binding molecules are of particular use in pharmaceutical compositions for the treatment of diseases related to cellular aberrancies, such as cancers and autoimmune diseases.

Abstract: Described are proteinaceous molecules comprising at least two, preferably three to six, binding domains that bind specifically to at least two different binding sites on aberrant cells. These multi-domain and multi-specific binding molecules are preferably used in selectively modulating biological processes. The provided binding molecules are of particular use in pharmaceutical compositions for the treatment of diseases related to cellular aberrancies, such as cancers and autoimmune diseases.

Abstract: A method for eradicating tumor cells expressing on their surface a MHC-peptide complex comprising a peptide derived from MAGE comprising contacting the cell with at least one immune effector cell through specific interaction of a specific binding molecule for the MHC-peptide complex. Described are bispecific immunoglobulins of which one arm specifically binds to a MHC-MAGE-derived peptide complex associated with aberrant cells, and the other arm specifically recognizes a target associated with immune effector cells. A pharmaceutical composition comprising such bispecific antibody and suitable diluents and/or excipients and a T cell comprising a T-cell receptor or a chimeric antigen receptor recognizing a MHC-peptide complex comprising a peptide derived from MAGE-A is described, as well as a method of producing a T cell comprising introducing into the T-cell nucleic acids encoding an ? chain and a ? chain or a chimeric antigen receptor.

Abstract: Described are immunoglobulins provided with a toxic moiety, comprising at least an immunoglobulin variable region that specifically binds to an MHC-peptide complex preferentially associated with aberrant cells. These immunoglobulins provided with a toxic moiety may be used in selectively modulating biological processes. These immunoglobulins provided with a toxic moiety are of particular use in pharmaceutical compositions for the treatment of diseases related to cellular aberrations, such as cancers and autoimmune diseases.

Abstract: Described are immunoglobulins provided with a toxic moiety, comprising at least an immunoglobulin variable region that specifically binds to an MHC-peptide complex preferentially associated with aberrant cells. These immunoglobulins provided with a toxic moiety are preferably used in selectively modulating biological processes. The provided immunoglobulins provided with a toxic moiety are of particular use in pharmaceutical compositions for the treatment of diseases related to cellular aberrancies, such as cancers and autoimmune diseases.

Abstract: A first aspect of the disclosure relates to the field of binding molecules targeted at pathogens. The disclosure further relates to proteinaceous binding molecules targeting cells displaying pathogen-associated molecular patterns, in particular targeting cell surface molecules associated with or derived from pathogens, more in particular cell surface proteins displaying peptides from intracellular (pathogen associated) proteins.

Abstract: Described are immunoglobulins provided with a toxic moiety, comprising at least an immunoglobulin variable region that specifically binds to an MHC-peptide complex preferentially associated with aberrant cells. These immunoglobulins provided with a toxic moiety are preferably used in selectively modulating biological processes. The provided immunoglobulins provided with a toxic moiety are of particular use in pharmaceutical compositions for the treatment of diseases related to cellular aberrancies, such as cancers and autoimmune diseases.

Abstract: A first aspect of the disclosure relates to the field of binding molecules targeted at pathogens. The disclosure further relates to proteinaceous binding molecules targeting cells displaying pathogen-associated molecular patterns, in particular targeting cell surface molecules associated with or derived from pathogens, more in particular cell surface proteins displaying peptides from intracellular (pathogen associated) proteins.

Abstract: Described are proteinaceous molecules comprising at least a domain that comprises an amino acid sequence that specifically binds to an MHC-peptide complex on an aberrant cell, functionally connected with a substance that induces apoptosis in aberrant cells, but not in normal cells. These proteinaceous molecules are preferably used in selectively modulating biological processes. The provided proteinaceous molecules are of particular use in pharmaceutical compositions for the treatment of diseases related to cellular aberrancies, such as cancers.

Abstract: Described are proteinaceous molecules comprising at least a domain that comprises an amino acid sequence that specifically binds to an MHC-peptide complex on an aberrant cell, functionally connected with a substance that induces apoptosis in aberrant cells, but not in normal cells. These proteinaceous molecules are preferably used in selectively modulating biological processes. The provided proteinaceous molecules are of particular use in pharmaceutical compositions for the treatment of diseases related to cellular aberrancies, such as cancers.

Abstract: Described are immunoglobulins provided with a toxic moiety, comprising at least an immunoglobulin variable region that specifically binds to an MHC-peptide complex preferentially associated with aberrant cells. These immunoglobulins provided with a toxic moiety are preferably used in selectively modulating biological processes. The provided immunoglobulins provided with a toxic moiety are of particular use in pharmaceutical compositions for the treatment of diseases related to cellular aberrancies, such as cancers and autoimmune diseases.

Abstract: A first aspect of the disclosure relates to the field of binding molecules targeted at pathogens. The disclosure further relates to proteinaceous binding molecules targeting cells displaying pathogen-associated molecular patterns, in particular targeting cell surface molecules associated with or derived from pathogens, more in particular cell surface proteins displaying peptides from intracellular (pathogen associated) proteins.

Abstract: Described are immunoglobulins provided with a toxic moiety, comprising at least an immunoglobulin variable region that specifically binds to an MHC-peptide complex preferentially associated with aberrant cells. These immunoglobulins provided with a toxic moiety are preferably used in selectively modulating biological processes. The provided immunoglobulins provided with a toxic moiety are of particular use in pharmaceutical compositions for the treatment of diseases related to cellular aberrancies, such as cancers and autoimmune diseases.

Abstract: An inhaler for delivering dry-powder medicament to a patient from an open blister pocket of a blister pack. The blister pack has a plurality of blister pockets spaced apart in a length direction of the pack and each containing a measured dose of the medicament. The inhaler includes a housing for enclosing used and unused portions of the blister pack together with a medicament dispensing mechanism for opening the blister pockets of the blister pack. The inhaler also includes a manifold through which air can be drawn in use of the inhaler, the manifold including an air inlet for receiving external air, at least one medicament aperture for communicating with an opened pocket of the blister pack to enable entrainment of the medicament by the air drawn through the manifold, and an air outlet for delivery of the entrained medicament to the patient.

Abstract: An inhaler for delivering dry-powder medicament to a patient from an open blister pocket of a blister pack. The blister pack is in the form of a flexible elongate strip including a base sheet having a plurality of recesses spaced along its length and a cover sheet peelably sealed to the base sheet to define a plurality of blister pockets each containing a measured dose of the medicament. The inhaler also includes a housing for enclosing used and unused portions of the blister pack together with the medicament dispensing mechanism. The housing defines internal transverse walls extending in the width direction of the blister pack for isolating the used portion of the cover sheet from the unused portion of the blister pack.

Abstract: An inhaler for delivering dry-powder medicament to a patient from an open blister pocket of a blister pack. The inhaler includes a housing for enclosing used and unused portions of the blister pack together with a medicament dispensing mechanism. The inhaler also includes a manifold through which air can be drawn in use of the inhaler, the manifold including an air inlet for receiving external air, at least one medicament aperture for communicating with an opened pocket of the blister pack to enable entrainment of the medicament by the air drawn through the manifold, and an air outlet for delivery of the entrained medicament to the patient. The medicament dispensing mechanism includes a guide surface for guiding the cover sheet of the unused portion of the blister pack. The manifold and the guide surface are defined by separate components of the inhaler.

Abstract: Described are methods for testing at least one effect of a pharmaceutical substance in a subject, which include administering a pharmaceutical substance to the subject, measuring with at least one sensor contained within a mobile sensor system, at the subject or in close proximity to the subject, at least one parameter value indicative of a the subject's body function, transmitting at least one sensor system signal associated with the at least one parameter value to a receiver contained within a mobile base unit, the receiver being provided with a means for wireless transmission, and wirelessly transmitting a mobile base unit signal associated with the at least one sensor system signal from the receiver to a back-end system, wherein at least the back-end system correlates the at least one parameter value with and/or displays a representation of the at least one effect of the pharmaceutical substance.